Pipeline

i n f l a r x

Loading

Development Pipeline

Home R & D Pipeline

Pipeline

COVID 19 & ARDS

Program

Preclinical

Phase 1

Phase 2

Phase 3

Market

Status & Milestones

Vilobelimab
C5a inhibitor

Critical COVID-19

SARS-CoV-2-induced ARDS

Approved by European Commission*

Broader ARDS

Phase 2 "Just Breathe" ASPR/BARDA clinical platform study

INFLAMMATION & IMMUNOLOGY (I&I)

Program

Preclinical

Phase 1

Phase 2

Phase 3

Market

Status & Milestones

INF904
oral C5aR inhibitor

Chronic spontaneous urticaria (CSU)

Data anticipated in summer 2025

Hidradenitis suppurativa (HS)

Data anticipated in summer 2025

Other immuno-dermatology

Additional indications in immuno-dermatology

IFX002
C5a inhibitor

Vilobelimab Life-cycle approach

For optimized use in chronic inflammatory indications

INF904
oral C5aR inhibitor

various

Additional chronic indications in I&I including neurology, nephrology, hematology and others

*Commercial partnering and distribution options in the EU being considered.

See also in R&D: